Debjit Chattopadhyay
Stock Analyst at Guggenheim
(4.58)
# 227
Out of 5,090 analysts
110
Total ratings
58%
Success rate
21.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Buy | $32 → $39 | $26.42 | +47.62% | 1 | Dec 4, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $28 → $43 | $29.70 | +44.78% | 8 | Nov 18, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $22 → $19 | $22.08 | -13.95% | 7 | Nov 5, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Buy | $30 | $9.21 | +225.73% | 1 | Oct 15, 2025 | |
| QURE uniQure | Maintains: Buy | $28 → $95 | $20.88 | +354.98% | 7 | Sep 25, 2025 | |
| PEPG PepGen | Reiterates: Buy | $6 | $5.40 | +11.11% | 2 | Sep 24, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $90 → $92 | $81.32 | +13.13% | 6 | Sep 23, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $15 | $9.75 | +53.85% | 3 | Sep 22, 2025 | |
| MAZE Maze Therapeutics | Maintains: Buy | $19 → $34 | $41.72 | -18.50% | 3 | Sep 15, 2025 | |
| SLNO Soleno Therapeutics | Reiterates: Buy | $106 | $51.17 | +107.15% | 5 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $10 | $9.03 | +10.74% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $14 | $9.42 | +48.62% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $106 | $53.09 | +99.66% | 4 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $558 → $546 | $455.52 | +19.86% | 8 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $64 | $36.90 | +73.44% | 3 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $20.57 | +143.13% | 5 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $189 | $230.65 | -18.06% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $55 | $27.39 | +100.80% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.73 | +382.57% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $13.46 | +26.30% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $9.96 | +50.60% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $56.45 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.96 | +283.06% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.25 | +418.26% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $35.07 | -14.46% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.43 | +1,927.97% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $457.51 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $5.18 | +440.54% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $7.50 | +166.67% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $31.62 | +288.99% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $26.43 | +104.31% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.14 | +5,186.34% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.17 | - | 3 | Jun 26, 2017 |
Pharvaris
Dec 4, 2025
Maintains: Buy
Price Target: $32 → $39
Current: $26.42
Upside: +47.62%
Centessa Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $28 → $43
Current: $29.70
Upside: +44.78%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Buy
Price Target: $22 → $19
Current: $22.08
Upside: -13.95%
Lexeo Therapeutics
Oct 15, 2025
Initiates: Buy
Price Target: $30
Current: $9.21
Upside: +225.73%
uniQure
Sep 25, 2025
Maintains: Buy
Price Target: $28 → $95
Current: $20.88
Upside: +354.98%
PepGen
Sep 24, 2025
Reiterates: Buy
Price Target: $6
Current: $5.40
Upside: +11.11%
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $90 → $92
Current: $81.32
Upside: +13.13%
Rezolute
Sep 22, 2025
Reiterates: Buy
Price Target: $15
Current: $9.75
Upside: +53.85%
Maze Therapeutics
Sep 15, 2025
Maintains: Buy
Price Target: $19 → $34
Current: $41.72
Upside: -18.50%
Soleno Therapeutics
Aug 27, 2025
Reiterates: Buy
Price Target: $106
Current: $51.17
Upside: +107.15%
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $9.03
Upside: +10.74%
Aug 13, 2025
Maintains: Buy
Price Target: $45 → $14
Current: $9.42
Upside: +48.62%
Aug 6, 2025
Maintains: Buy
Price Target: $101 → $106
Current: $53.09
Upside: +99.66%
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $455.52
Upside: +19.86%
Jun 20, 2025
Reiterates: Buy
Price Target: $64
Current: $36.90
Upside: +73.44%
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $20.57
Upside: +143.13%
May 7, 2025
Maintains: Buy
Price Target: $195 → $189
Current: $230.65
Upside: -18.06%
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $27.39
Upside: +100.80%
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.73
Upside: +382.57%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $13.46
Upside: +26.30%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.96
Upside: +50.60%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $56.45
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.96
Upside: +283.06%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $4.25
Upside: +418.26%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $35.07
Upside: -14.46%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.43
Upside: +1,927.97%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $457.51
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $5.18
Upside: +440.54%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $7.50
Upside: +166.67%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $31.62
Upside: +288.99%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $26.43
Upside: +104.31%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.14
Upside: +5,186.34%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $27.17
Upside: -